Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Ritchie, Craig W.a | Black, Christopher M.b | Khandker, Rezaul K.b | Wood, Robertc | Jones, Eddiec; * | Hu, Xiaohand | Ambegaonkar, Baishali M.b
Affiliations: [a] Centre for Dementia Prevention, Centre for Clinical Brain Sciences, University of Edinburgh, UK | [b] Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA | [c] Adelphi Real World, Macclesfield, UK | [d] University of Southern California, Los Angeles, CA, USA
Correspondence: [*] Correspondence to: Eddie Jones, BSc, Director, Neurology, Adelphi Real World, Macclesfield, UK. Tel.: +44 1625 577336; E-mail: eddie.jones@adelphigroup.com.
Abstract: To ensure that patients with dementia and their caregivers receive appropriate treatment and support, early diagnosis is essential but remains challenging. Real-world data from a multi-national, cross-sectional survey of physicians and their patients were analyzed to quantify the diagnostic pathway for dementia, including a focus on severity of patients’ cognitive impairment (CI) at the time of symptom onset, referral and subsequent diagnosis. Data were collected for 7,620 patients with CI. Most patients saw a healthcare professional within 1 year of first symptoms and received a diagnosis within 3–7 months of initial consultation. However, only 20% of patients received a diagnosis before their disease progressed beyond the prodromal stage and 23.5% already had moderate CI at diagnosis. These findings show that the goal of identifying and diagnosing CI at the earliest stages of disease is, for many patients, not achieved. Efforts toward public awareness and proactive, earlier detection and intervention, must be maintained—indeed where possible invigorated.
Keywords: Caregivers, cognitive impairment, consultation, diagnosis, earlier and intervention, early diagnosis, prodromal, real-world, referral
DOI: 10.3233/JAD-170864
Journal: Journal of Alzheimer's Disease, vol. 62, no. 1, pp. 457-466, 2018
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl